39 results on '"Rosti, Giovanni"'
Search Results
2. A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial
- Author
-
Leyvraz, Serge, Pampallona, Sandro, Martinelli, Giovanni, Ploner, Ferdinand, Perey, Lucien, Aversa, Savina, Peters, Solange, Brunsvig, Paal, Montes, Ana, Lange, Andrzej, Yilmaz, Ugur, and Rosti, Giovanni
- Subjects
Chemotherapy -- Health aspects ,Chemotherapy -- Comparative analysis ,Lung cancer, Small cell -- Drug therapy ,Cancer -- Chemotherapy ,Cancer -- Health aspects ,Cancer -- Comparative analysis ,Health - Abstract
Background The dose intensity of chemotherapy can be increased to the highest possible level by early administration of multiple and sequential high-dose cycles supported by transfusion with peripheral blood progenitor cells (PBPCs). A randomized trial was performed to test the impact of such dose intensification on the long-term survival of patients with small cell lung cancer (SCLC). Methods Patients who had limited or extensive SCLC with no more than two metastatic sites were randomly assigned to high-dose (High, n = 69) or standard-dose (Std, n = 71) chemotherapy with ifosfamide, carboplatin, and etoposide (ICE). High-ICE cycles were supported by transfusion with PBPCs that were collected after two cycles of treatment with epidoxorubicin at 150 mg/[m.sup.2], paclitaxel at 175 mg/[m.sup.2], and filgrastim. The primary outcome was 3-year survival. Comparisons between response rates and toxic effects within subgroups (limited or extensive disease, liver metastases or no liver metastases, Eastern Cooperative Oncology Group performance status of 0 or 1, normal or abnormal lactate dehydrogenase levels) were also performed. Results Median relative dose intensity in the High-ICE arm was 293% (range = 174%-392%) of that in the Std-ICE arm. The 3-year survival rates were 18% (95% confidence interval [CI] = 10% to 29%) and 19% (95% CI = 11% to 30%) in the High-ICE and Std-ICE arms, respectively. No differences were observed between the High-ICE and Std-ICE arms in overall response (n = 54 [78%, 95% CI = 67% to 87%] and n = 48 [68%, 95% CI = 55% to 78%], respectively) or complete response (n = 27 [39%, 95% CI = 28% to 52%] and n = 24 [34%, 95% CI = 23% to 46%], respectively). Subgroup analyses showed no benefit for any outcome from High-ICE treatment. Hematologic toxicity was substantial in the Std-ICE arm (grade [greater than or equal to] 3 neutropenia, n = 49 [70%]; anemia, n = 17 [25%]; thrombopenia, n = 17 [25%]), and three patients (4%) died from toxicity. High-ICE treatment was predictably associated with severe myelosuppression, and five patients (8%) died from toxicity. Conclusions The long-term outcome of SCLC was not improved by raising the dose intensity of ICE chemotherapy by threefold.
- Published
- 2008
3. Prognostic factors for survival in patients with advanced renal cell carcinoma undergoing nonmyeloablative allogeneic stem cell transplantation
- Author
-
Peccatori, Jacopo, Barkholt, Lisbeth, Demirer, Tanner, Sormani, Maria Pia, Bruzzi, Paolo, Ciceri, Fabio, Zambelli, Alberto, Da Prada, Gian Antonio, Pedrazzoli, Paolo, Siena, Salvatore, Massenkeil, Gero, Martino, Rodrigo, Lenhoff, Stig, Corradini, Paolo, Rosti, Giovanni, Ringden, Olle, Bregni, Marco, and Niederwieser, Dietger
- Subjects
Cancer patients -- Prognosis ,Carcinoma, Renal cell -- Care and treatment ,Homografts -- Patient outcomes ,Stem cells -- Transplantation ,Stem cells -- Usage ,Stem cells -- Patient outcomes ,Health - Published
- 2005
4. Salvage hign-dose chemotherapy in patients with germ cell tumors
- Author
-
Rosti, Giovanni, De Giorgi, Ugo, Salvioni, Roberto, Papiani, Giorgio, Sebastiani, Loretta, Monti, Giuseppe, Ferrante, Patrizia, Pizzocaro, Giorgio, Marangolo, Maurizio, and Argnani, Marzia
- Subjects
Cancer -- Research ,Chemotherapy -- Health aspects ,Germ cell tumors ,Cancer patients -- Care and treatment ,Health - Published
- 2002
5. Primary mediastinal germ cell tumors
- Author
-
Rosti, Giovanni, Secondino, Simona, Necchi, Andrea, Fornarini, Giuseppe, and Pedrazzoli, Paolo
- Abstract
Germ cell tumors (GCTs) are a group of neoplasms usually arising in the gonads, and very rarely in sites outside the gonads, mainly in the retroperitoneum, the anterior mediastinum, and pineal gland or the coccyx (mainly in childhood). The prognosis of nonseminoma primary mediastinal GCTs (PMGCTs), is considered to be poorer compared to its retroperitoneal or gonadal counterparts and, according to the International Germ Cell Cancer Collaborative Group, it is considered by definition as a “poor risk” disease.
- Published
- 2019
- Full Text
- View/download PDF
6. Secondary malignancies after high-dose chemotherapy in germ cell tumor patients: a 34-year retrospective study of the European Society for Blood and Marrow Transplantation (EBMT)
- Author
-
Necchi, Andrea, Lo Vullo, Salvatore, Secondino, Simona, Rosti, Giovanni, Badoglio, Manuela, Giannatempo, Patrizia, Raggi, Daniele, Lanza, Francesco, Chabannon, Christian, Bonini, Chiara, Mariani, Luigi, and Pedrazzoli, Paolo
- Abstract
We aimed to assess the incidence and risk factors of secondary malignancy (SM) in the young adult patients who received high-dose chemotherapy (HDCT) for germ cell tumors (GCT). The EBMT database was interrogated. Criteria for patient selection included adult male GCT and HDCT administered in any line of therapy. Cumulative incidence methods were used to estimate the time-to-SM diagnosis. Univariable Fine and Gray proportional hazard regression evaluated risk factors of SM occurrence. From 1981 to 2015, 9153 autografts were identified. Among 5295 patients, 59 cases of SM, developed after a median follow-up of 3.8 years, were registered. Of these patients, 23 (39%) developed hematologic SM, 34 (57.6%) solid SM (two patients had uncoded SM). Twenty-year cumulative incidence of solid versus hematologic SM was 4.17% (95% CI: 1.78–6.57) versus 1.37% (95% CI: 0.47–2.27). Median overall survival after SM was significantly shorter for patients who developed hematologic SM versus solid SM (8.6 versus 34.4 months, p= 0.003). Age older than 40 years at the time of HDCT was significantly associated with hematologic, but not solid, SM development (p= 0.004 versus p= 0.234). SM occurrence post-HDCT showed different patterns of incidence and mortality in GCT. These data may be important to optimize patient selection, counseling and follow-up after HDCT.
- Published
- 2018
- Full Text
- View/download PDF
7. Salvage High-Dose Chemotherapy for Relapsed Pure Seminoma in the Last 10 Years: Results From the European Society for Blood and Marrow Transplantation Series 2002-2012
- Author
-
Necchi, Andrea, Lo Vullo, Salvatore, Bregni, Marco, Rosti, Giovanni, Mariani, Luigi, Raggi, Daniele, Giannatempo, Patrizia, Secondino, Simona, Schumacher, Kathrin, Massard, Christophe, Kanfer, Edward, Oechsle, Karin, Laszlo, Daniele, Michieli, Mariagrazia, Ifrah, Norbert, Mercier, Melanie, Crysandt, Martina, Wuchter, Patrick, Nagler, Arnon, Wahlin, Anders, Martino, Massimo, Badoglio, Manuela, Pedrazzoli, Paolo, and Lanza, Francesco
- Abstract
In a retrospective analysis of data from 13 European Society for Blood and Marrow Transplantation (EBMT) centers, we evaluated the contemporary outcomes of high-dose chemotherapy (HDCT) as salvage therapy of advanced seminoma. The results supported the use of HDCT, particularly for patients with chemosensitive disease. This proof of concept needs to be prospectively validated in a randomized trial of HDCT versus standard-dose chemotherapy.
- Published
- 2017
- Full Text
- View/download PDF
8. Germ Cell Tumors Overexpress the Candidate Therapeutic target Cyclin B1 Independently of p53 function
- Author
-
De Giorgi, Ugo, Yuan, Juping, Moroni, Mauro, Veronese, Silvio, Sartore-Bianchi, Andrea, Broggini, Massimo, Rosti, Giovanni, Strebhardt, Klaus, and Ruffini, Pier Adelchi
- Abstract
Germ cell tumors (GCTs) generally express wild-type p53 protein. Rare p53 mutations may be associated with cisplatin resistance. There is growing interest in the role of cyclins as targets for GCTs. Cyclin B1 is involved in G2/M transition and its overexpression has been reported in tumors carrying nonfunctional p53. Conversely, cyclin B1-specific small interfering RNAs have been shown to dramatically reduce tumor proliferation. We investigated whether a subset of chemotherapy-resistant GCTs overexpressed cyclin B1 as a result of nonfunctional p53, as this would make cyclin B1 a potential therapeutic target. Our data showed that GCTs consistently overexpressed cyclin B1 independently of their responsiveness to chemotherapy or the presence of p53 mutations. Cyclin B1 was overexpressed by GCT cell lines carrying functional p53. Cyclin B1-specific small interfering RNAs only slightly reduced the proliferation of JAR and JEG-3 placental choriocarcinoma cells. Further research into targeting cyclin B1 could provide a novel intervention for GCTs.
- Published
- 2015
- Full Text
- View/download PDF
9. High-dose chemotherapy for germ cell tumors: do we have a model?
- Author
-
Necchi, Andrea, Lanza, Francesco, Rosti, Giovanni, Martino, Massimo, Farè, Elena, and Pedrazzoli, Paolo
- Abstract
Introduction:Since the late nineties, the intensification of chemotherapy doses with hematopoietic stem cell rescue held promise for patients with advanced and poor prognosis germ cell tumors (GCTs). High-dose chemotherapy (HDCT) has, nowadays, a recognized indication in the salvage setting of advanced GCTs and is steadily utilized worldwide.Areas covered:We evaluated the available data with the use of HDCT in these patients. In addition, we provided an original perspective on several issues as experts on behalf of the European Society for Blood and Marrow Transplantation and IGG, including peripheral blood stem cells mobilization and the use of HDCT in special subpopulations of GCT, with the aim to help clarify critical issues in the absence of available clear-cut information.Expert opinion:Despite HDCT being currently considered a therapeutic option in the salvage setting, critical questions regarding patient selection are still unanswered. Eligibility of patients with a chemoresistant disease, the use of available prognostic factors as well as tumor marker decline in clinical practice are pending issues. Moving forward, these are critical arguments in favor of further clinical research in the field of advanced GCTs.
- Published
- 2015
- Full Text
- View/download PDF
10. Chemotherapy-Induced Nausea and Vomiting in Italian Cancer Centers: Results of CINVDAY, a Prospective, Multicenter Study
- Author
-
De Tursi, Michele, Carella, Consiglia, Tomao, Silverio, Cinieri, Saverio, Lorusso, Vito, Marchetti, Paolo, Vecchio, Stefania, Sansoni, Elisabetta, Contu, Antonio, Adamo, Vincenzo, Silvestris, Nicola, Nuzzo, Antonio, Rosti, Giovanni, Ravaioli, Alberto, Danova, Marco, Tonini, Giuseppe, Passalacqua, Rodolfo, Cruciani, Giorgio, Faedi, Marina, Spada, Massimiliano, De Laurentiis, Michelino, Amoroso, Domenico, Tomao, Federica, Sperduti, Isabella, Grassadonia, Antonino, Tinari, Nicola, Natoli, Clara, and Iacobelli, Stefano
- Abstract
Purpose Guideline consistency in the prevention of chemotherapy-induced nausea and vomiting (CINV) remains low (29% in the Pan European Emesis Registry study) and very low (11%) in regimens with a high emetogenic risk. The aim of this study was to evaluate the guideline consistency of CINV prophylaxis for acute emesis in daily clinical practice in Italy.Methods This was a prospective, observational, multicenter study. Patients scheduled to receive antitumor treatment on a single prespecified day were included. Data on patient characteristics (demographic and clinical), type of anticancer therapy, and type of antiemetic therapy prescribed for acute emesis were collected on electronic data capture forms. Chemotherapy regimens and antiemetic prophylaxis were categorized according to the MASCC 2011 guidelines. The study was approved by the local ethics committees.Results From July 2013 to February 2014, a total of 502 patients were enrolled at 26 study sites. Median age was 62 years (range 27–87 years). Colorectal cancer and breast cancer were the most common malignancies. The emetogenic potential of the chemotherapy regimens used was high (HEC) (23.7%), moderate (MEC) (40.6%), low (31.3%) or minimal (4.4%). Overall, guideline consistency was 19.3%. Consistency reached 45% when the various 5HT3 receptor antagonists were considered equivalent and interchangeable in MEC regimens. Adherence to guidelines was lowest for MEC and MINIMAL risk groups. Ten percent of patients in HEC and MEC regimens did not receive any 5HT3 receptor antagonists. NK1 receptor antagonists were used in 8% of all regimens.Conclusions Our study indicates that antiemetic guideline inconsistency remains an issue in daily clinical oncology practice in Italy.
- Published
- 2014
- Full Text
- View/download PDF
11. Standard vs Adapted Sunitinib Regimen in Elderly Patients With Metastatic Renal Cell Cancer: Results From a Large Retrospective Analysis
- Author
-
De Giorgi, Ugo, Scarpi, Emanuela, Sacco, Cosimo, Aieta, Michele, Lo Re, Giovanni, Sava, Teodoro, Masini, Cristina, De Vincenzo, Fabio, Baldazzi, Valentina, Camerini, Andrea, Fornarini, Giuseppe, Burattini, Luciano, Rosti, Giovanni, Ferrari, Vittorio, Moscetti, Luca, Chiuri, Vincenzo Emanuele, Luzi Fedeli, Stefano, Amadori, Dino, and Basso, Umberto
- Abstract
In a retrospective study, we assessed the routine use of first-line sunitinib in 185 elderly patients with metastatic renal cell cancer (mRCC). There were no substantial differences in outcome between the standard and adapted sunitinib regimens, but the adapted was better tolerated. A sunitinib adapted regimen (AR) could be considered as an option in selected older patients.
- Published
- 2014
- Full Text
- View/download PDF
12. Autologous stem cell transplantation: is it still relevant in breast cancer?
- Author
-
Pedrazzoli, Paolo, Bregni, Marco, Rosti, Giovanni, Lanza, Francesco, and Demirer, Taner
- Published
- 2013
- Full Text
- View/download PDF
13. Critical issues on high-dose chemotherapy with autologous hematopoietic progenitor cell transplantation in breast cancer patients
- Author
-
Martino, Massimo, Bottini, Alberto, Rosti, Giovanni, Generali, Daniele, Secondino, Simona, Barni, Sandro, Maisano, Roberto, Lanza, Francesco, Castagna, Luca, and Pedrazzoli, Paolo
- Abstract
Introduction:High-dose chemotherapy (HDC) with autologous hematopoietic progenitor cell transplantation (AHPCT) for high-risk (HR) or metastatic breast cancer (MBC) is no longer an option.Areas covered:An expert panel including medical oncologists and hematologists produce an opinion paper on the use of HDC and AHPCT in BC patients and they explain why they believe that; despite inconclusive results thus far, this treatment should have an ongoing role in breast cancer management under clinical trials.Expert opinion:HDC with AHPCT has become a safe treatment modality and an advantage in disease-free survival has been observed in most of the studies with HDC, with the caveat that today, even a limited relapse-free survival and progression-free survival benefit is sufficient for the approval of new antineoplastic agents. Moreover, in HRBC, an overall survival benefit by HDC could be achieved in the HER2-ve and triple-negative populations and, in this setting, HDC with AHPCT represents a therapeutic option that can be proposed to well-informed patients. In MBC, the HDC approach should be investigated further in selected patients with HER2-ve, chemosensitive disease. This paper is not intended to give any conclusion, but rather to open a debate on the value of HDC in HR and MBC.
- Published
- 2012
- Full Text
- View/download PDF
14. Nutritional intervention for improving treatment tolerance in cancer patients
- Author
-
Paccagnella, Agostino, Morassutti, Ildamaria, and Rosti, Giovanni
- Abstract
This study aims to assess various types of nutritional intervention for improving treatment tolerance in patients with malnutrition related to the cancer anorexia-cachexia syndrome.
- Published
- 2011
- Full Text
- View/download PDF
15. Expectations of survivors, caregivers and healthcare providers for testicular cancer survivorship and quality of life
- Author
-
De Padova, Silvia, Rosti, Giovanni, Scarpi, Emanuela, Salvioni, Roberto, Amadori, Dino, and De Giorgi, Ugo
- Abstract
Aims and background We compared expectations of testicular cancer survivors and their caregivers with those of healthcare providers for testicular cancer survivorship care and quality of life to identify experiences and potential expectations in which there was disagreement.Methods In a meeting with testicular cancer survivors, their caregivers, and care providers with an interest in testicular cancer, we distributed a structured questionnaire with 24 questions divided into 3 sections: personal information, information on the quality of life of survivors, information on the role of care providers, general practitioners and health-related internet sources in the expectations of survivors.Results The overall response rate was 91% (29 of 32) for patients and 100% (14 of 14) for caregivers with all questionnaires evaluable, while among 60 care providers, 42 (70%) responded with 41 (68%) evaluable. Between patients/caregivers and care providers, expectations were most incongruent for the role of primary care physicians in testicular cancer follow-up: important/fundamental for 58% of patients/caregivers and 88% of care providers (P = 0.010). Comparing patients/caregivers with care providers in their views of the experience of testicular cancer survivorship, we found several discrepancies: the fear of recurrence was high/very high for 18 of 43 (42%) patients/caregivers and in the perception of 40 of 41 (98%) care providers (P <0.001), and psychological distress was considered as highly relevant by 35% of patients/caregivers and 93% of care providers (P <0.001).Conclusions Patients/caregivers and care providers have different perceptions of survivors' experiences and discordant expectations with respect to the roles of primary care providers in testicular cancer survivorship care. Uncertainties about the roles and responsibilities of physicians can lead to deficiencies in care, supporting the need to make survivorship care planning a standard component in cancer management.
- Published
- 2011
- Full Text
- View/download PDF
16. Cost-Effectiveness of Pegfilgrastim versus Six Days of Filgrastim for Preventing Febrile Neutropenia in Breast Cancer Patients
- Author
-
Danova, Marco, Chiroli, Silvia, Rosti, Giovanni, and Doan, Quan V
- Abstract
Aims and background Febrile neutropenia (FN) is a major complication of chemotherapy and is associated with substantial morbidity, mortality and costs. The aim of this study was to evaluate the cost-effectiveness of primary prophylaxis with pegfilgrastim versus six-day filgrastim in preventing FN in Italian patients with early-stage breast cancer receiving adjuvant chemotherapy associated with a ≥20% FN risk.Methods The pharmacoeconomic evaluation was based on a decision-analytic model taking into account the possible consequences of FN (e.g., death and reduction/delay of chemotherapy dose). Parameters included in the model were relative risk of FN with pegfilgrastim versus six-day filgrastim; direct costs (drug purchase and FN-related hospitalizations); relative risk of relative dose intensity <85% with pegfilgrastim versus filgrastim; impact on long-term survival due to relative dose intensity <85%; and impact of age on FN and relative dose intensity <85%.Results Under base-case assumptions, pegfilgrastim was cost-effective compared to six-day filgrastim in Italy. The estimated cost, life expectancy and quality-adjusted life years per person for pegfilgrastim were € 3078, 16.47 years, and 15.32; the corresponding figures for six-day filgrastim were € 3033, 16.35 years, and 15.22. The corresponding incremental cost-effectiveness ratio with pegfilgrastim was € 409 per life-year gained and € 429 per quality-adjusted life year gained. One-way sensitivity analyses showed that the results were most sensitive to the relative risk of FN for 6-day filgrastim versus pegfilgrastim. The results were moderately sensitive to the cost of pegfilgrastim and filgrastim, cost of drug administration, cost of FN hospitalization, and number of chemotherapy cycles. Pegfilgrastim remained cost-effective, with an incremental cost-effectiveness ratio well below the accepted limit of € 50,000 per life year gained in all one-way sensitivity analyses. A two-way sensitivity analysis on cost of drugs showed a range of pegfilgrastim dominance over six-day filgrastim.Conclusions At the current official price in Italy, primary prophylaxis with pegfilgrastim improved health outcomes with a very limited cost increase for the National Health Service payer. Even when very low prices of filgrastim and high prices of pegfilgrastim were considered in the model, the resulting incremental cost-effectiveness ratio remained well within the acceptable cost-effectiveness limit of € 50,000/quality-adjusted life year.
- Published
- 2009
- Full Text
- View/download PDF
17. Transplantation of allogeneic hematopoietic stem cells: an emerging treatment modality for solid tumors
- Author
-
Demirer, Taner, Barkholt, Lisbeth, Blaise, Didier, Pedrazzoli, Paolo, Aglietta, Massimo, Carella, Angelo Michele, Bay, Jacques-Olivier, Arpaci, Fikret, Rosti, Giovanni, Gurman, Gunhan, Niederwieser, Dietger, and Bregni, Marco
- Abstract
Allogeneic non-myeloablative stem-cell transplantation is feasible for patients with various refractory and advanced solid tumors. Current data suggest that the graft-versus-tumor effect associated with this approach might prolong survival of some patients with metastatic solid tumors. The authors discuss the latest results from the literature and recent data from the European Bone Marrow Transplantation Solid Tumors Working Party.
- Published
- 2008
- Full Text
- View/download PDF
18. IGG* Practice Guidelines on Germ Cell Tumor in Adult Male Patients
- Author
-
De Giorgi, Ugo, Nicolai, Nicola, Tana, Silvia, Tavolini, Ivan Matteo, Palazzi, Silvia, Bracarda, Sergio, Tedeschi, Lucilla, Palmieri, Giovannella, Frassineti, Luca, Da Pozzo, Luigi, Pastorino, Ugo, Emiliani, Ermanno, Marangolo, Maurizio, Pizzocaro, Giorgio, Rosti, Giovanni, and Salvioni, Roberto
- Abstract
Germ cell tumors are rare neoplasms that affect young males. Nearly 99% of patients with localized stage I disease and nearly 80% of patients with metastatic disease can be cured. Even patients who relapse following chemotherapy can achieve a long-term survival in approximately 30–40% of cases. The main objective in early stages and in good prognosis patients has changed in recent years, and it has become of major importance to reduce treatment-related morbidity without compromising the excellent long-term survival rate. In poor prognosis patients, there is a correlation between the experience of the treating institution and the long-term clinical outcome of the patients, particularly when the most sophisticated therapies are needed. So far, of utmost importance is the information from updated practice guidelines for the diagnosis and treatment of germ cell tumors. The Italian Germ cell cancer Group (IGG) has developed the following clinical recommendations, which identify the current standards in diagnosis and treatment of germ cell tumors in adult males.
- Published
- 2008
- Full Text
- View/download PDF
19. High-Dose Chemotherapy With Autologous Hematopoietic Stem Cell Support for Solid Tumors in Adults
- Author
-
Pedrazzoli, Paolo, Rosti, Giovanni, Secondino, Simona, Carminati, Ornella, and Demirer, Taner
- Abstract
Supported by experimental evidence and convincing results of early phase II studies, since the 1980s high-dose chemotherapy (HDC) with autologous hematopoietic stem cell support (AHSCT) has been uncritically adopted by many oncologists as a potentially curative option for several solid tumors. As a result, the number (and size) of randomized trials comparing this approach with conventional chemotherapy initiated (and often abandoned before completion) in this setting was limited and the benefit of a greater escalation of dose of chemotherapy with stem cell transplantation in solid tumors remains, with the possible exception of breast carcinoma (BC) and germ cell tumors (GCT), largely unsettled. In this article, we review and comment on the data from studies to date of HDC for solid tumors in adults.
- Published
- 2007
- Full Text
- View/download PDF
20. Testicular tumors
- Author
-
Rosti, Giovanni, Carminati, Ornella, Casanova, Claudia, and Papiani, Giorgio
- Abstract
Abstract: Germ cell tumors of the testes represent a unique paradigm of diseases which can be cured even in extremely advanced phase. Unfortunately, this makes them unique among adult solid tumors. Seminoma and non seminoma are relatively rare with approximatively 25,000 patients in Europe per year, but numbers are increasing world wide. Different strategies are needed depending on stage and prognostic scores. Seminoma is extremely sensitive to radiation therapy and chemotherapy, while all germ cell tumors show a very good response to chemotherapy. Clinical stage I seminoma is currently treated with radiation, single course carboplatin or surveillance policy. Clinical stage I non seminoma can also be approached with different strategies such as retroperitoneal lymph node dissection, observation or one-two courses of standard chemotherapy. Stage II seminoma may be treated with either radiation or chemotherapy, while for all advanced stages chemotherapy is mandatory. Since the mid-eighties PEB (Cisplatin, Etoposide and Bleomycin) is the regimen of choice and no other schedule has proved superior in terms of efficacy. Surgery on the residual disease is crucial to the whole strategy and should be performed or attempted in all cases. Consequently, the correct treatment strategy for these tumors does not depend only on the ability of a single physician, but on a skilled team specialized in this particular tumor. Second line therapies (VeIP, PEI, TIP) can cure 25%–40% of patients, but improved strategies for resistant tumors are desperately needed. High-dose chemotherapy has shown very good results in some studies while being less impressive in others. In any case, it should remain an option for relapsing patients and could be used in some cases of upfront chemotherapy in patients with slow marker decline, but this should only be considered in referring centers.
- Published
- 2007
- Full Text
- View/download PDF
21. Perché Parlare di Epoetine Oggi? Opinioni a Confronto
- Author
-
Barni, Sandro and Rosti, Giovanni
- Published
- 2006
- Full Text
- View/download PDF
22. Meeting Report: Breast Cancer in the Older Woman
- Author
-
Martoni, Andrea, Cucinotta, Domenico, Balducci, Lodovico, Aapro, Matti, Anisimov, Vladimir, Ausili-Cefaro, Giampiero, Bernabei, Roberto, Caraceni, Augusto, Costa, Alberto, Crivellali, Diana, Daidone, M. Grazia, Extermann, Martine, Fabris, Fabrizio, Franceschi, Claudio, Hayman, James A., Lelli, Giorgio, Masina, Alceste, Monfardini, Silvio, Mustacchi, Giorgio, Piana, Edera, Repetto, Lazzaro, Della Cuna, Gioacchino Robustelli, Rosti, Giovanni, Valagussa, Pinuccia, Taffurelli, Mario, Tanneberger, Stephan, Torta, Riccardo, Zamagni, Claudio, and Zappa, Marco
- Published
- 2004
- Full Text
- View/download PDF
23. High-dose Chemotherapy in Small Cell Lung Cancer
- Author
-
Pasini, Felice, Pelosi, Giuseppe, De Manzoni, Giovanni, and Rosti, Giovanni
- Abstract
Improvements in small cell lung cancer (SCLC) therapy with conventional doses of drugs with or without radiotherapy have been poor, and the 5-year survival is discouraging. Since SCLC is highly sensitive to radiotherapy and chemotherapy, some studies have tried to improve survival by increasing the dose of the drugs. Within conventional ranges, dose intensity can be increased with the support of hematopoietic growth factors (G/GM-CSF) and/or shortening treatment intervals (eg weekly regimens). However, dose intensity could be increased by only 20-30% and a survival advantage was not definitively obtained. Given its high chemosensitivity already two decades ago, SCLC was one of the first malignancies deemed suitable for maximizing dose and dose intensity with the support of autologous bone marrow transplantation (ABMT). On the whole, results were disappointing and the procedure was nearly abandoned. Nowadays, some interest is emerging again due to the improvements in supportive care such as the availability of hematopoietic growth factors and the peripheral blood progenitor cells (PBPC).
- Published
- 2002
- Full Text
- View/download PDF
24. Feasibility and long‐term results of autologous PBSC transplantation in recurrent undifferentiated nasopharyngeal carcinoma
- Author
-
Airoldi, Mario, De Crescenzo, Alberto, Pedani, Fulvia, Marchionatti, Sara, Gabriele, Anna Maria, Succo, Giovanni, Rosti, Giovanni, and Bumma, Cesare
- Published
- 2001
- Full Text
- View/download PDF
25. Allogeneic stem cell transplantation for solid tumors
- Author
-
Prosper, Felipe and Rosti, Giovanni
- Abstract
Reduction in morbidity and mortality associated with the use of allogeneic stem cell transplantation has prompted interest in exploiting the allogeneic T-cell immune-mediated antitumor effect to treat patients with chemotherapy-resistant solid tumors. Preliminary results in animal models and in patients with breast cancer, and more recently in patients with renal cell carcinoma, have provided the first evidence of a clinically significant graft-versus-tumor effect resulting in responses up to 50 in diseases refractory to chemotherapy. Better knowledge of antigens against which donor T lymphocytes may react and development of techniques aimed to increase antitumor response without increasing graft-versus-host reaction or rejection are necessary before allogeneic transplantation becomes a standard therapy for solid tumors.
- Published
- 2001
26. Metastases to the Submaxillary Gland from Breast Cancer: Case Report
- Author
-
Rosti, Giovanni, Callea, Antonina, Merendi, Rino, Beccati, Donatella, Tienghi, Amelia, Turci, Daniele, and Marangolo, Maurizio
- Abstract
A case of metastases to the submaxillary gland from breast carcinoma is reported. The patient, a 68-year-old female, had been operated for a stage II N+ breast carcinoma 4 years before. She then received six courses of CMF adjuvant program. A literature review is presented concerning the 8 well-documented cases reported.
- Published
- 1987
- Full Text
- View/download PDF
27. Clinical Relevance of Bone Marrow Biopsy in Staging and Follow-Up of Breast Cancer
- Author
-
Cruciani, Giorgio, Fiorentini, Gian Maria, Rosti, Giovanni, Tienghi, Amelia, Bardella, Daniele, Magni, Ettore, and Marangolo, Maurizio
- Abstract
Bone marrow biopsies by Jamshidi needle were performed in 106 breast cancer female patients. Sixty-four of them were in follow-up after mastectomy, and neoplastic involvement of marrow was found in 21 patients (32.8%). Among the 42 women undergoing staging before mastectomy, the incidence of marrow involvement was 11.9% (5 women, all with radiographic positivity). Of the 37 women, either in follow-up or in the staging phase, with bone metastases detected by roentgenographic and isotopic examination, the bone biopsy was positive in 23 (62.1%), and 7 histologically had micrometastases. Three women, without any radiographic or isotopic sign of metastases, had positive biopsies. A good correlation was found between the hydroxyproline:creatinine ratio and neoplastic involvement of bone marrow.
- Published
- 1983
- Full Text
- View/download PDF
28. Cyclophosphamide, Methotrexate, 5-Fluorouracil, Alternating with Adriamycin and Mitomycin C in Metastatic Breast Cancer: A Pilot Study
- Author
-
Cruciani, Giorgio, Tienghi, Amelia, Molinari, Anna Lia, Fiorentini, Giammaria, Rosti, Giovanni, Turci, Daniele, and Marangolo, Maurizio
- Abstract
To explore the clinical applicability of the Goldie and Coldman hypothesis, we treated 28 patients with metastatic breast cancer with alternating non-cross-resistant chemotherapy. The patients received cyclophosphamide, 600 mg/m2, 5-fluorouracil, 600 mg/m2, methotrexate, 40 mg/m3, alternated every three weeks with adriamycin, 60 mg/m2, and mitomycin C, 10 mg/m2. Only one patient had previously received palliative chemotherapy. Six patients had received adjuvant CMF, and 17 patients had been pretreated with endocrine therapy (13 for advanced disease, 4 as adjuvant). Fourteen patients had bone involvement, and 10 had visceral metastases. A mean of 12 cycles was given to 24 evaluable patients. The objective response rate was 67%: 11 patients (46%) achieved complete and 5 (21%) partial remission. Response rate in soft tissues was 83.3%, in bone 50%, in liver 100%, and in lung 80%. The median duration of response was 14 months, with 7 patients still in remission. No life-threatening toxicity was observed. Our preliminary results support the validity of this approach and the efficacy of this combination chemotherapy. A large-scale randomized study is warranted.
- Published
- 1987
- Full Text
- View/download PDF
29. An Italian Experience of High-Dose Chemotherapy and Autologous Bone Marrow Transplantation (ABMT) in Germ Cell Tumours. Suggestions for Future Direction
- Author
-
Rosti, Giovanni, Albertazzi, Livia, Tienghi, Amelia, Fiorentini, Giammaria, Turci, Daniele, Cruciani, Giorgio, Flamini, Manuela, Argnani, Marzia, Bassetto, Maria Antonietta, Salvioni, Roberto, and Marangolo, Maurizio
- Abstract
In this paper an Italian cooperative trial investigates the role of a high-dose regimen with carboplatin, etoposide and ifosfamide in germ cell tumours. Twenty-eight patients underwent one or two transplants. Seventeen with progressive disease. Nine in sensitive relapse and two with stable disease after salvage therapy. Toxicity was generally moderate: two deaths occurred at day 15 from ABMT (one from VOD and one from tumour growth). Five patients are alive and disease free at least 10 months follow-up. In highly pre-treated patients this high-dose combination seems to give an option of cure for relapsed patients. Early transplantation is suggested.
- Published
- 1992
- Full Text
- View/download PDF
30. The use of Granulocyte Colony-Stimulating Factors following Peripheral Blood Progenitor Cell Rescue after High-Dose Chemotherapy for Advanced Breast Cancer: A Prospective Study
- Author
-
Dazzi, Claudio, Albertazzi, Livia, Rosti, Giovanni, Maestri, Antonio, Fiorentini, Giammaria, Leoni, Maurizio, Tienghi, Amelia, Turci, Daniele, Ferrante, Patrizia, Vertogen, Bernadette, Cariello, Anna, Latino, Walter, Zumaglini, Federica, and Marangolo, Maurizio
- Abstract
The use of high-dose chemotherapy followed by hematopoietic rescue is increasing worldwide for solid tumors. Several studies have suggested that the period of absolute neutrophil count (ANC, <500/ml) may be shortened in patients who receive peripheral blood progenitor cells (PBPC). To estimate the clinical value of granulocyte-colony-stimulating factor, we examined a cohort of 26 consecutive patients with advanced breast cancer who received one or two cycles of high-dose chemotherapy with PBPC rescue with or without filgrastim. Thirty-five courses of high-dose ICE (ifosfamide, carboplatin, etoposide) chemotherapy were administered and evaluated. All patients received PBPC rescue. Sixteen patients (21 courses) received subcutaneous filgrastim (5 mg/kg) following PBPC infusion. Recovery to ≥ 500 ANC occurred at a median time of 7 days post PBPC infusion among patients who received filgrastim versus 10 days among patients who received standard support care only (P<0.01). The administration of filgrastim was not associated with a reduction in the duration of hospitalization, in the total number of days on nonprophylactic antibiotics, number of red blood cell transfusions, time to platelet engraftment, or number of febrile days. This could be the consequence of the high hematopoietic cell dose administered in the study. Therefore, any effect of filgrastim was probably masked by the use of a large number of PBPC. Larger prospective randomized studies, specifically focused on the utility of the administration of growth factors following high-dose chemotherapy and PBPC rescue, may be warranted to know whether the administration of filgrastim after PBPC transplantation is really necessary.
- Published
- 1997
- Full Text
- View/download PDF
31. Phase II study of intensive chemotherapy with carboplatin, ifosfamide and etoposide plus recombinant human granulocyte colony-stimulating factor and sequential radiotherapy in locally advanced, unresectable non-small-cell lung cancer
- Author
-
Scagliotti, Giorgio Vittorio, Ricardi, Umberto, Crinó, Lucio, Maranzano, Ernesto, Marinis, Filippo De, Morandi, Maria Grazia, Meacci, Luisa, Marangolo, Maurizio, Emiliani, Ermanno, Rosti, Giovanni, Figoli, Franco, Bolzicco, Gianfranco, Masiero, Paolo, Gentile, Alfonso, and Tonato, Maurizio
- Abstract
Abstract: From June 1991 to August 1994, 61 patients with stage III unresectable non-small-cell lung cancer (NSCLC; 16 cases of stage IIIA with N2 bulky disease and 45 cases of stage IIIB) were treated with ifosfamide given i.v. at 3 g/m
2 on day 1, carboplatin given i.v. at 200 mg/m2 on days 1 and 2, etoposide given i.v. at 120 mg/m2 on days 1–3 (ICE) and recombinant human granulocyte colony-stimulating factor (rhG-CSF) given s.c. at 5 μg/kg on days 4–13. Chemotherapy was given every 3 weeks for up to three cycles and, unless the disease progressed, was followed by thoracic radiotherapy on the tumor volume (total dose 60 Gy) and mediastinum (40 Gy). All patients had measurable or evaluable unresectable disease and a performance status (Eastern Cooperative Oncology Group) of 0–1. Only 61% of the enrolled patients received the full program of chemoradiotherapy according to the study design. At the end of sequential chemo-radiothera-peutic treatment, 41% of the patients had an objective response (24 partial responses and 1 complete response), 31% showed no change and 28% had progressive disease. The response rate noted for patients in stage IIIA with N2 bulky disease and that recorded for patients in stage IIIB did not differ significantly. The median time to progression was 5.4 months and the median survival was 8.2 months, with the 1-year survival rate being 31%. Sites of progression were mostly intrathoracic. Haematological toxicity was the main side effect, with grade III–IV thrombocytopenia being reported in 24% of the 165 courses of intensive ICE chemotherapy given. Febrile neutropenia was described in six courses (three patients). Non-haematological toxicities and radiotherapy-related side effects were generally mild and easily manageable. In conclusion, in unresectable stage III NSCLC a short program of moderately intensified ICE chemotherapy with rhG-CSF protection followed by sequential radiotherapy failed to increase the percentage of objective responses and reached a median survival comparable with that previously achieved with standard doses.- Published
- 1996
- Full Text
- View/download PDF
32. Psychosocial Morbidity and Adjustment to Illness Among Long-Term Cancer Survivors
- Author
-
Grassi, Luigi and Rosti, Giovanni
- Abstract
Psychiatric morbidity (DSM-III-R) and adjustment to illness (psychological stress, illness behavior, and coping) were prospectively studied in 52 cancer patients who had been evaluated at the time of cancer diagnosis 6 years earlier. The prevalence of psychiatric disorders decreased from 47% to 37%. Improvement in psychological adjustment (low interpersonal sensitivity, psychoticism, paranoia, disease conviction, and anxious preoccupation) was found between these two assessment points. A lifetime history of psychopathology and psychiatric problems at baseline was associated with a current mental disorder. External locus of control, low social support, abnormal illness behavior, emotional stress, and poor coping mechanisms, as evaluated at first assessment, were also associated with psychological symptoms and maladjustment to cancer at follow-up. From the data reported, the need to maintain a continuity of psychosocial care among cancer survivors is inferred.
- Published
- 1996
- Full Text
- View/download PDF
33. Primary Lymphoma of the Central Nervous System
- Author
-
Amadori, Marinella, Maltoni, Marco, Ravaioli, Alberto, Rosti, Giovanni, Pasquini, Enzo, Leoni, Maurizio, and Amadori, Dino
- Abstract
Primary lymphoma of the central nervous system (CNS) represents a pathology that is no longer considered rare, also in the light of its high correlation with the human immunodeficiency virus (HIV) syndrome reported recently. Often the correct diagnosis of the disease is difficult to reach, owing to the wide spectrum of non-lymphoma pathologies from which it should be differentiated and the invasiveness of some diagnostic techniques. The biologic aggressiveness of the neoplasm often makes a combined radio-chemotherapeutic approach necessary. In contrast, surgical resection does not seem to provide any significant benefit. The clinical experience reported here, together with a review of the most recent literature, lead the authors to suggest the opportunity of treating primary lymphoma of the CNS with the most active and modern chemotherapeutic protocols in association with traditional treatments to obtain an improvement in overall survival.
- Published
- 1991
- Full Text
- View/download PDF
34. Prognostic Factors and Survival in Non-Hodgkin's Lymphomas: The Experience of the Istituto Oncologico Romagnolo (IOR)
- Author
-
Pasquini, Enzo, Nicolini, Mario, Rosti, Giovanni, Amadori, Marinella, Pileri, Stefano, Nanni, Oriana, Fattori, Pier Paolo, Marangolo, Maurizio, Amadori, Dino, and Ravaioli, Alberto
- Abstract
In an attempt to evaluate natural history, prognostic factors and survival, the data of 340 patients with NHL were collected. 267 patients were evaluable for the analysis of prognostic factors and survival. The tumor samples were reviewed and reclassified according to the Kiel classification. At completion, 180 patients were affected by low-grade (LG)-NHL and 87 patients had high-grade (HG)-NHL. Numerous potential prognostic factors were analysed in univariate and multivariate analyses.Globally 154 patients (57.4%) obtained complete remission (CR) and 65 patients (24.3%) partial remission (PR). The response rate was similar in LG and HG-NHL groups. 5-years survival was 52% for all patients (53% in LG-NHL and 44% in HG-NHL). Median survival was 62 months in LG-NHL and 38 months in HG-NHL (p = n.s.).At the univariate analysis overall survival (OS) in LG-NHL was favourably influenced by age <65 years (p = 0.004), performance status >80 (p < 0.02), early clinical stage (p < 0.001), absence of systemic symptoms (p < 0.001), low serum LDH (p < 0.001) and achievement of CR (p < 0.001), while in the HG-NHL only by age (p = 0.005) and achievement of CR (p < 0.001).The multivariate analysis showed early clinical stage, low serum LDH, absence of systemic symptoms and achievement of CR as independent prognostic factors in LG-NHL and only achievement of CR in HG-NHL.The univariate analysis for disease free survival (DFS) showed age (p < 0.001), clinical stage (p < 0.001), systemic symptoms (p < 0.001), serum LDH (p < 0.001) and bulky disease (p = 0.03) as prognostic factors in LG-NHL and age (p = 0.006) in HG-NHL.At the multivariate analysis early clinical stage and low serum LDH appeared as independent prognostic factors in LG-NHL, whereas it was age in HG-NHL.Age and achievement of CR appear to be the most important prognostic factors for OS and DFS both in LG and HG-NHL and, in particular, the achievement of CR is extremely important in improving the prognosis regardless of the type of therapy adopted. In the near future the maximum effort should be made to ameliorate the quality of the treatments in an aim to attain the CR so as to have the opportunity to cure the largest possible number of patients with NHL.
- Published
- 1994
- Full Text
- View/download PDF
35. Clinical Activity and Cardiac Tolerability of Non-Pegylated Liposomal Doxorubicin in Breast Cancer: A Synthetic Review
- Author
-
Airoldi, Mario, Amadori, Dino, Barni, Sandro, Cinieri, Saverio, De Placido, Sabino, Di Leo, Angelo, Gennari, Alessandra, Iacobelli, Stefano, Ionta, Maria Teresa, Lorusso, Vito, Lotrionte, Marzia, Marchetti, Paolo, Mattioli, Rodolfo, Minotti, Giorgio, Pronzato, Paolo, Rosti, Giovanni, Tondini, Carlo Alberto, and Veronesi, Andrea
- Published
- 2011
- Full Text
- View/download PDF
36. Mitoxantrone (M) and Vinblastine (V) in the Treatment of Advanced Breast Cancer
- Author
-
Cruciani, Giorgio, Tienghi, Amelia, Fiorentini, Giammaria, Rosti, Giovanni, Turci, Daniele, Salerno, Vincenzo, Leoni, Maurizio, and Marangolo, Maurizio
- Abstract
Twenty-four patients with metastatic breast cancer, all but 1 pretreated with one or more chemotherapeutic regimens, were entered in a pilot study to assess toxicity and efficacy of the combination mitoxantrone and vinblastine. Dominant sites of metastases were viscera in 9 patients, bone in 10 and soft tissues in 5. All patients received mitoxantrone 10 mg/m2i.v. on day 1 and vinblastine 1.7 mg/m2by 4 hour infusion on days 3, 4 and 5, every 3-4 weeks. Objective responses (1 CR, 7 PR) were observed in 8 (38%) of the 21 evaluable patients. Median duration of response was 10.5 months. Of 12 patients pretreated with an anthracycline containing regimen, 4 responded (1 CR and 3 PR). Major toxicity was myelosuppression, grade 4 in 2 cases and grade 3 in 2 others. No evident alopecia was observed and only 1 case of grade 1 cardiac toxicity. In conclusion, mitoxantrone followed by vinblastine is an effective regimen in metastatic breast cancer also in pretreated patients, and previous anthracycline administration does not seem to reduce the percentage of response. Moreover, toxicity is generally mild.
- Published
- 1990
- Full Text
- View/download PDF
37. Are metastatic testicular tumors curable with high-dose chemotherapy and stem-cell rescue?
- Author
-
Rosti, Giovanni, De Giorgi, Ugo, and Pedrazzoli, Paolo
- Published
- 2008
- Full Text
- View/download PDF
38. High-Dose Chemotherapy With Autologous Hematopoietic Stem Cell Transplantation for High-Risk Primary Breast Cancer
- Author
-
Pedrazzoli, Paolo, Martino, Massimo, Delfanti, Sara, Generali, Daniele, Rosti, Giovanni, Bregni, Marco, Lanza, Francesco, Party, Solid Tumor Working, Blood, on behalf of the European Group for, and (EBMT), Marrow Transplantation
- Abstract
Background: The efficacy of high-dose chemotherapy (HDC) and autologous hematopoietic stem cell transplantation for breast cancer (BC) has been an area of intense controversy among the medical oncology community. Over the last decade, due to the presentation of negative results from early randomized studies, this approach has not longer been considered an option by the vast majority of medical oncologists. This article is aimed to clarify what happened and where we are now in this not exhausted field.Methods: We critically revised the published literature regarding HDC in the setting of high-risk BC, including a recent meta-analysis using individual patient data from 15 randomized studies.Results: A significant benefit by HDC in recurrence-free survival has been clearly documented in unselected patient populations. In HER2-negative population, particularly in the triple-negative disease, a positive effect of intensified therapy in overall survival is biologically plausible and supported by clinical evidence. Over the years HDC with support of adequate number of stem cells has become a safe treatment modality.Conclusions: The administration of higher doses of chemotherapy with stem cell support may still represent a therapeutic option (and not a recommendation) in selected BC patients. This approach should be investigated further.- Published
- 2015
- Full Text
- View/download PDF
39. Salvage Chemotherapy for Recurrent Invasive Thymoma
- Author
-
Musi, Marco, Di Vito, Francesco, and Rosti, Giovanni
- Published
- 1997
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.